Rocket Pharmaceuticals (RCKT) said Monday that, while the Phase 2 trial for its experimental RP-L301 gene therapy is ready for patient enrollment, it will not begin until next year as the company is currently directing resources toward other programs.
RP-L301 is being studied for the treatment of Pyruvate Kinase Deficiency, a red blood cell disorder that causes mild to life-threatening anemia.
The company, meanwhile, said its RP-A501 gene therapy is generally well-tolerated in a phase 1 trial to treat male patients with Danon Disease, a genetic disorder characterized by the weakening of the heart muscle.
Rocket said the adverse events after patient dosing were mostly mild or moderate and not related to RP-A501 and non-serious.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。